AI-driven technology to transform launch of National Lung Cancer Screening Program

An Australian medtech company has signed a strategic agreement to introduce AI-powered screening software for the National Lung Cancer Screening Program (NLCSP), set to launch in July.

The partnership between ParagonCare and South Korea’s Coreline Soft leverages the AVIEW product line, a suite of 3D CT image analysis solutions. Notably, AVIEW LCS Plus enables simultaneous screening for lung cancer, emphysema, and coronary artery calcification – three critical indicators in lung cancer detection.

“By integrating AI-powered healthcare solutions into our portfolio, ParagonCare is reinforcing its commitment to advancing patient care and streamlining radiology workflows. Our partnership with Coreline Soft is a significant step forward in harnessing innovative technology to support healthcare professionals and improve patient outcomes,” said Tiffany Chiew, General Manager, Capital and Service at ParagonCare.

The AI-driven technology enhances large-scale data analysis, improves nodule detection precision, and reduces diagnostic variability among radiologists. Already implemented in lung cancer screening programs across South Korea and Europe, including Germany and Italy, the software is now set to support Australian healthcare providers.

The partnership is being officially launched today at the Australian Lung Cancer Conference (ALCC) 2025. The event brings together leading researchers, clinicians, and policymakers to discuss advancements and challenges in lung cancer diagnosis, treatment, and prevention.

“Partnering with ParagonCare is a significant step in expanding access to our AI lung cancer screening solutions across Australia,” said Jason Suh, Director of Overseas Business Department at Coreline Soft.

“With their deep expertise in medical imaging and strong local presence, ParagonCare is an ideal partner to bring advanced screening technology to more healthcare providers. Together, we aim to enhance early detection, improve diagnostic accuracy, and support better patient outcomes – starting with the NLCSP in July.”

In reimagining healthcare across the entire patient journey, Health Industry Hub^TM is the only one-stop-hub uniting the diversity of the Pharma, MedTech, Diagnostics & Biotech sectors to inspire meaningful change.

The Health Industry Hub^TM content is copyright protected. Access is available under individual user licenses. Please click here to subscribe and visit T&Cs here.